The fate of certain popular contraceptives is up in the air pending public meetings to be held December 8 and 9 by the U.S. Food and Drug Administration (FDA). Two FDA committees will jointly hear presentations on the risks and benefits of contraceptives containing drospirenone (a synthetic progestin hormone) in combination with ethinyl estradiol (an [...]
Continue Reading





